Psychedelics should be at forefront of EU mental health efforts, urges PAREA
The Psychedelic Access and Research Alliance (PAREA) has released a position statement calling on the EU to harness psychedelics in a bid to create innovation in the area of mental health treatments and make the Union a leader in biomedicines.
Data shows that in 2019, 7.2% of the EU population aged 15 years and older were living with chronic depression. However, mental health treatment in Europe has seen little to no innovation in decades.
Highlighting that the right to innovation is enshrined in the European Charter of Patients’ Rights, the position statement is a response to the EU Pharmaceutical Package revision and extends its reach to cover the full lifecycle of medicines, underscoring the urgent need to incentivise the development of novel mental health treatments.READ MORE